文献速递脑血管病

血清肝细胞生长因子与急性缺血性卒中3个月预后相关

Serum Hepatocyte Growth Factor Is Probably Associated With 3-Month Prognosis of Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2018-01-10

该研究基于CATIS试验的事后分析,纳入3027例急性缺血性卒中患者,探讨血清肝细胞生长因子(HGF)与3个月预后的关联。多因素校正后,HGF最高四分位组较最低组主要结局(死亡或重大残疾)风险增加(OR 1.50,95%CI 1.10-2.03;Ptrend=0.015)。HGF与主要结局的关联受肝素预处理修饰(Pinteraction=0.001),仅在无肝素预处理患者中呈线性剂量反应关系。

要点

  • 基线卒中越严重,血清HGF水平越高。
  • HGF升高与3个月死亡或重大残疾风险独立相关。
  • 肝素预处理可能修饰HGF与预后的关联。

核心结论

  • 血清HGF水平在基线卒中更严重者中更高,且升高可能与缺血性卒中患者3个月不良预后独立相关,尤其见于无肝素预处理者。

研究设计与样本

  • CATIS试验事后分析,纳入3027例急性缺血性卒中患者。

主要发现

  • 多因素校正后,HGF最高与最低四分位比较,主要结局风险增加(OR 1.50;95%CI 1.10-2.03;Ptrend=0.015)。
  • log转换HGF每增加1个标准差,主要结局风险增加14%(95%CI 2%-27%)。
  • 将HGF四分位加入常规危险因素模型改善预测能力(NRI 17.50%,P<0.001;IDI 0.23%,P=0.022)。
  • HGF与主要结局关联受肝素预处理修饰(Pinteraction=0.001),无肝素预处理者呈线性剂量反应(Plinearity<0.001),有肝素预处理者无此关系。

临床怎么用

  • 血清HGF可能作为急性缺血性卒中3个月预后评估的辅助指标。
  • 解读HGF预后价值时需考虑肝素预处理的影响。

局限性

  • 研究为事后分析,需其他缺血性卒中样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Serum hepatocyte growth factor (HGF) is positively associated with poor prognosis of heart failure and myocardial infarction, and it can also predict the risk of ischemic stroke in population. The goal of this study was to investigate the association between serum HGF and prognosis of ischemic stroke. METHODS: A total of 3027 acute ischemic stroke patients were included in this post hoc analysis of the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). The primary outcome was composite outcome of death or major disability (modified Rankin Scale score ≥3) within 3 months. RESULTS: After multivariate adjustment, elevated HGF levels were associated with an increased risk of primary outcome (odds ratio, 1.50; 95% confidence interval, 1.10-2.03; Ptrend=0.015) when 2 extreme quartiles were compared. Each SD increase of log-transformed HGF was associated with 14% (95% confidence interval, 2%-27%) increased risk of primary outcome. Adding HGF quartiles to a model containing conventional risk factors improved the predictive power for primary outcome (net reclassification improvement: 17.50%, P<0.001; integrated discrimination index: 0.23%, P=0.022). The association between serum HGF and primary outcome could be modified by heparin pre-treatment (Pinteraction=0.001), and a positive linear dose-response relationship between HGF and primary outcome was observed in patients without heparin pre-treatment (Plinearity<0.001) but not in those with heparin pre-treatment. CONCLUSIONS: Serum HGF levels were higher in the more severe stroke at baseline, and elevated HGF levels were probably associated with 3-month poor prognosis independently of stroke severity among ischemic stroke patients, especially in those without heparin pre-treatment. Further studies from other samples of ischemic stroke patients are needed to validate our findings.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zhu Z, Xu T, Guo D, et al. Serum Hepatocyte Growth Factor Is Probably Associated With 3-Month Prognosis of Acute Ischemic Stroke. Stroke. 2018. PMID: 29321335. doi:10.1161/STROKEAHA.117.019476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。